$90.00 - $90.00
Human Angiotensin III is a seven-amino-acid renin–angiotensin system peptide generated from Angiotensin II by removal of its N-terminal Asp residue.
The resulting sequence, Arg-Val-Tyr-Ile-His-Pro-Phe (RVYIHPF), retains much of the receptor-interacting region of Angiotensin II while presenting a different N-terminal structure.
Product Information
| Property | Specification |
|---|---|
| Product Name | Angiotensin III, Human |
| Catalog No. | AS2617 |
| CAS No. | 13602-53-4 |
| Sequence | Arg-Val-Tyr-Ile-His-Pro-Phe |
| One-Letter Sequence | RVYIHPF |
| Peptide Length | 7 amino acids |
| Molecular Formula | C46H66N12O9 |
| Molecular Weight | Approximately 931.10 Da |
| Synonym | Angiotensin II (2-8) |
| Research Areas | RAS signaling, aldosterone regulation, receptor pharmacology, peptide metabolism |
| Purity | Crude to 98% |
Formation from Angiotensin II
Angiotensin III is produced through aminopeptidase-mediated removal of the N-terminal Asp1 residue of Angiotensin II:
DRVYIHPF → RVYIHPF
This single-residue processing step changes the N-terminal chemistry while retaining seven residues of the parent octapeptide.
Receptor and Aldosterone Research
Angiotensin III can interact with angiotensin receptor systems and has been used extensively to investigate aldosterone secretion, cardiovascular signaling and central RAS biology.
Its pharmacological profile should be evaluated independently from Angiotensin II because peptide processing can alter receptor potency, tissue response and metabolic stability.
We consider Angiotensin II and Angiotensin III a useful paired system for studying how a single N-terminal truncation changes the behavior of a vasoactive peptide.
Peptide Metabolism
Angiotensin III is also an intermediate in continuing angiotensin metabolism. Further aminopeptidase processing produces shorter RAS peptides, including Angiotensin IV.
This makes the peptide useful for studies that focus on dynamic angiotensin processing as well as receptor pharmacology.
Experimental Planning
Peptide identity, salt form and concentration should be defined when literature data are compared. Free Angiotensin III is associated with CAS 13602-53-4, while acetate-containing forms can carry different registry information.
Researchers selecting material for sensitive receptor or cellular assays can review our Recommended Peptide Purity guidance.
Frequently Asked Questions
How does Angiotensin III differ from Angiotensin II?
Angiotensin III lacks the N-terminal Asp residue of Angiotensin II and therefore contains seven amino acids instead of eight.
What is another name for Angiotensin III?
It is commonly described as Angiotensin II (2-8), reflecting its relationship to residues 2 through 8 of Angiotensin II.
Can shorter angiotensin fragments be synthesized?
Defined truncations, species variants and modified angiotensin peptides can be evaluated through Chemical Peptide Synthesis.